Announcements Trials
Browse Landscape

Status

Approved for marketing 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 11Recurrence 9Neoplasms 6Multiple Myeloma 6Breast Neoplasms 6Small Cell Lung Carcinoma 3Lymphoma, Mantle-Cell 3Lymphoma, Large B-Cell, Diffuse 3Lung Neoplasms 3Leukemia, Myeloid, Acute 3Leukemia, Lymphocytic, Chronic, B-Cell 3HER2-positive Breast Cancer 3Glioma 3Carcinoma, Medullary 3Thyroid Neoplasms 2Stomach Neoplasms 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Neuroendocrine Tumors 2Neoplasm Metastasis 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Head and Neck Neoplasms 2Cholangiocarcinoma 2Carcinoma, Transitional Cell 2Carcinoma, Renal Cell 2Carcinoma, Basal Cell 2Waldenstrom Macroglobulinemia 1Urogenital Neoplasms 1Tumors Harboring NTRK Fusion 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Approved for marketing × INDUSTRY × EGFRm Advanced Non-Small Cell Lung Cancer × Clear all
NCT06279728 2025-07-03

Medical Access Program for Datopotamab Deruxtecan in EGFRm NSCLC Patients

Daiichi Sankyo

Approved for marketing
Thoracic

EGFRm Advanced Non-Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡